Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ulrich Jaeger

Showing results (101-110 of 109) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 109 results.
The Lancet. Haematology|June 27, 2020
Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trialNagesh Kalakonda, Marie Maerevoet, Federica Cavallo, et al.
Nature Medicine|October 16, 2012
PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomasDaniela Laimer, Helmut Dolznig, Karoline Kollmann, et al.
American Journal of Hematology|April 16, 2026
Safety and Effectiveness of Sutimlimab in Cold Agglutinin Disease: A Real-World International ExperienceBruno Fattizzo, Elisa Sambruna, Yoshitaka Miyakawa, et al.
Blood|June 17, 2018
Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapyEdit Porpaczy, Sabrina Tripolt, Andrea Hoelbl-Kovacic, et al.
The New England Journal of Medicine|June 3, 2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemiaJohn C Byrd, Jennifer R Brown, Susan O'Brien, et al.
Blood Advances|December 11, 2024
Safety and Efficacy of Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma in a Multinational Real-World StudyEvgenii Shumilov, Rebecca Wurm-Kuczera, Andrea Kerkhoff, et al.
Blood Advances|September 24, 2025
Patient-reported outcomes in patients with hematologic malignancies treated with CAR T-cell therapy in EuropeElise R A Pennings, Anne M Spanjaart, Frederick W Thielen, et al.
Science (New York, N.Y.)|April 6, 2023
Photovoltaics at multi-terawatt scale: Waiting is not an optionNancy M Haegel, Pierre Verlinden, Marta Victoria, et al.
Cancer Discovery|October 12, 2021
Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional RespondersChristoph Kornauth, Tea Pemovska, Gregory I Vladimer, et al.
Pageof 11

Showing results (101-110 of 109) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 109 results.
The Lancet. Haematology|June 27, 2020
Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trialNagesh Kalakonda, Marie Maerevoet, Federica Cavallo, et al.
Nature Medicine|October 16, 2012
PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomasDaniela Laimer, Helmut Dolznig, Karoline Kollmann, et al.
American Journal of Hematology|April 16, 2026
Safety and Effectiveness of Sutimlimab in Cold Agglutinin Disease: A Real-World International ExperienceBruno Fattizzo, Elisa Sambruna, Yoshitaka Miyakawa, et al.
Blood|June 17, 2018
Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapyEdit Porpaczy, Sabrina Tripolt, Andrea Hoelbl-Kovacic, et al.
The New England Journal of Medicine|June 3, 2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemiaJohn C Byrd, Jennifer R Brown, Susan O'Brien, et al.
Blood Advances|December 11, 2024
Safety and Efficacy of Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma in a Multinational Real-World StudyEvgenii Shumilov, Rebecca Wurm-Kuczera, Andrea Kerkhoff, et al.
Blood Advances|September 24, 2025
Patient-reported outcomes in patients with hematologic malignancies treated with CAR T-cell therapy in EuropeElise R A Pennings, Anne M Spanjaart, Frederick W Thielen, et al.
Science (New York, N.Y.)|April 6, 2023
Photovoltaics at multi-terawatt scale: Waiting is not an optionNancy M Haegel, Pierre Verlinden, Marta Victoria, et al.
Cancer Discovery|October 12, 2021
Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional RespondersChristoph Kornauth, Tea Pemovska, Gregory I Vladimer, et al.
Pageof 11